Single dose Imjudo + regular interval Imfinzi: the first anti-CTLA-4 + anti-PD-L1 combination indicated in unresectable hepatocellular carcinoma (uHCC) in the first-line setting1-3*
The recommended dose of Imjudo is 300 mg as a single dose, followed by Imfinzi 1500 mg at Day 1 of Cycle 1. Continue Imfinzi 1500 mg as a single agent every 4 weeks.
Please click the links above or the images below to download resources and view support materials to help manage patients taking Imfinzi and Imjudo.
About Imfinzi and Imjudo*Please see the Product Monograph for complete dosing and administration recommendations.
Would you like to receive updated Imfinzi and Imjudo resources or information on AstraZeneca Oncology products?
Be IN the know with Imfinzi’s + Imjudo’s HIMALAYA OS dataHIMALAYA: Primary OS analysis
(full analysis set; median duration of follow-up 33.2 [31.7-34.5] months Imfinzi + Imjudo, 32.6 [31.6-33.7] months Imfinzi, and 32.2 [30.4-33.7] months sorafenib)1,2†
Imfinzi + Imjudo: demonstrated statistically significant improvement in OS vs. sorafenib1,2,4
Adapted from the Imfinzi and Imjudo Product Monographs and
Abou-Alfa GK, et al.
Imfinzi + Imjudo reduced the risk of death by 24% vs. sorafenib (HR=0.76; 95% CI, 0.64-0.90; p=0.0013); event
rate: 262/393 vs. 293/389 sorafenib.
Progression-Free Survival (PFS):
HR=0.89; 95% CI, 0.76-1.04
Event rate: 335/393 (Imjudo + Imfinzi) vs. 327/389 (sorafenib)
† HIMALAYA was a randomized, open-label, multicentre, international phase III trial in patients with confirmed uHCC who did not receive prior systemic treatment. The study included patients with BCLC Stage C or B (not eligible for locoregional therapy), Child-Pugh Score Class A, and ECOG performance status
of 0 or 1. Patients were randomized 1:1:1 to receive Imfinzi 1500 mg (IV) Q4W plus a single priming dose of Imjudo 300 mg (IV) (n=393), Imfinzi 1500 mg (IV) Q4W alone (n=389) or sorafenib (oral) 400 mg BID (n=389). Treatment continued until disease progression or unacceptable toxicity. The primary objective was to assess the overall survival (OS) between the Imfinzi + Imjudo arm versus the sorafenib arm for superiority.
Mechanism of actionTremelimumab + durvalumab enhances antitumour T-cell activation and proliferation, helping to enhance antitumour immunity1,2†
Anti-CTLA-4 therapy tremelimumab has been shown to induce T-cell activation and expansion2
Watch the Imfinzi and Imjudo mechanisms of action
Nurse Kit Resources
imAR Handbook
High-level details concerning imAEs, how to recognize them, and how to manage them.
imAR Checklist
A concise checklist that allows you to run through potential imARs during your patient consultation.
Pocket Guide
A tool that you can carry with you at all times that provides an overview of imAEs and their management.
GP/Pharmacist ImAR Letter
To give to pharmacists and healthcare professionals in your centre/clinic so they can better understand the patient’s treatment and how to manage their potential side effects.
Patient Side Effects Tracker
Tear Pad
A tool for your patients to track and communicate their side effects in a clear and comprehensive table.
HCP Resources
PACIFIC Trail Paper
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
Reprint of the pivotal PACIFIC trial overall survival results, as published in the New England Journal of Medicine.
PACIFIC Postcard
Overview of the IMFINZI indication and its use in the PACIFIC Regimen.
For Patients
IMFINZI Note Card
A small card for patients to take notes when discussing their IMFINZI treatment plan.
Chemoradiation Therapy Postcard
An overview of the definitive platinum-based concurrent chemoradiation therapy (cCRT) regimens received by patients prior to their enrollment in the PACIFIC Study.
Clinical Efficacy and Dosing Guide
A review of IMFINZI clinical efficacy results from the PACIFIC trial, and recommended dosing and administration with adjustment guidance.
Dosing Guide
Provides information on the recommended dosing, preparation and administration of Imfinzi and Imjudo.
HIMALAYA:
5 Points of Interest
Provides information on 5 points of interest in the HIMALAYA trial.
Five-year HIMALAYA
Trial Paper
Rimassa L, Chan SL, Sangro B, et al. Five-year OS and survival by tumour response with tremelimumab plus durvalumab from the HIMALAYA study in unresectable HCC. J Hepatol. 2025;S0168-8278(25)00226-0. doi: 10.1016/j.jhep.2025.03.033.
Reprint of the 5-Year HIMALAYA trial results, as published in Journal of Hepatology.
Imfinzi
Product Monograph
Imjudo
Product Monograph
Patient Resources
Patient Information and
Side Effects Brochure
Provides patients with key information about
Imjudo and Imfinzi treatment and how to
recognize possible side effects.
Imfinzi Patient
Medication Information
Provides patients with information on what Imfinzi
is used for, how it works and how it’s given as well as
important safety information.
Imjudo Patient
Medication Information
Provides patients with information on what Imjudo
is used for, how it works and how it’s given as well as
important safety information.
Important Safety InformationImfinzi (durvalumab)
Indications and clinical use:
PrImfinzi ® (durvalumab) is indicated for the treatment of patients with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.1
Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).1
Imfinzi in combination with gemcitabine-based chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).1
Imfinzi, in combination with tremelimumab, is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.
- When using Imfinzi in combination with tremelimumab, consult the Product Monograph for Imjudo (tremelimumab) for further information on this drug.
Imfinzi, as monotherapy, is indicated for the first-line treatment of adult patients with uHCC who require systemic therapy.
The safety and efficacy of Imfinzi in patients younger than 18 years of age have not been established. Therefore, Health Canada has not authorized an indication for pediatric use.
No overall differences in safety or efficacy were reported between elderly patients (≥65 years of age) and younger patients (<65 years of age) who received Imfinzi.
Evidence from clinical studies suggests the use in the geriatric population may be associated with differences in safety in the uHCC population.
Contraindications:
Imfinzi is contraindicated in patients who are hypersensitive to durvalumab or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Most serious warnings and precautions:
Immune-mediated adverse reactions:
Imfinzi as monotherapy or in combination with other products can cause severe and fatal immune-mediated adverse reactions, including enterocolitis, intestinal perforation, hepatitis, dermatitis, Stevens-Johnson syndrome, endocrinopathy, pneumonitis, interstitial lung disease, myocarditis, neuropathy, encephalitis, myasthenia gravis, as well as toxicities in other organ systems. Immune-mediated adverse reactions have occurred at higher frequencies when Imfinzi is administered as a combination therapy with tremelimumab compared with Imfinzi as monotherapy.
Other relevant warnings and precautions:
- Administer under the supervision of health care professionals experienced in the treatment of cancer
- When using Imfinzi in combination with tremelimumab, consult the Imjudo (tremelimumab) Product Monograph for further information on this drug
- Driving and operating machinery
- No clinical data available for Child-Pugh Class B and C in patients with unresectable hepatocellular carcinoma
- Infections
- Infusion-related reactions
- Monitoring and laboratory tests – AST, ALT, bilirubin, renal, and thyroid function
- Fertility
- Pregnant and nursing women
- Elderly
For more information:
Please consult the Imfinzi Product Monograph for important information relating to adverse reactions, drug interactions and dosing, which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-668-6000.
Imjudo (tremelimumab)
Indications & clinical use:
Imjudo® (tremelimumab for injection) in combination with durvalumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.
- When using Imjudo in combination with durvalumab, consult Product Monograph for Imfinzi (durvalumab) for further information on this drug.
Evidence from clinical studies and experience suggests there were no overall differences in efficacy between patients 65 years or older and younger patients. Evidence from clinical studies suggests the use in the geriatric population may be associated with differences in safety in the uHCC population.
The safety and effectiveness of Imjudo in patients younger than 18 years of age have not been established. Therefore, Health Canada has not authorized an indication for pediatric use.
Contraindications:
Hypersensitivity to Imjudo or any ingredient in the formulation or component of the container.
Most serious warnings and precautions:
Immune-mediated adverse reactions:
Imjudo in combination with durvalumab can cause severe and fatal immune-mediated adverse reactions, including enterocolitis, intestinal perforation, hepatitis, dermatitis, Stevens-Johnson syndrome, endocrinopathy, pneumonitis, interstitial lung disease, myocarditis, neuropathy, encephalitis, myasthenia gravis, as well as toxicities in other organ systems
Other relevant warnings and precautions:
- Administer under the supervision of health care professionals experienced in the treatment of cancer
- When using Imjudo in combination with durvalumab, consult the Imfinzi (durvalumab) Product Monograph for further information on this drug
- Driving and operating machinery
- Lack of clinical data in uHCC for Child-Pugh Class B and C patients
- May require immunosuppression for imARs
- Other imARs (i.e., colitis/diarrhea, nephritis, rash, hypothyroidism/hyperthyroidism/thyroiditis, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis/hypopituitarism, other imARs, myasthenia gravis, myositis, polymyositis, Guillain-Barre Syndrome, arthritis, immune thrombocytopenia, pancreatitis, and hypoparathyroidism; immune-checkpoint reactions such as meningitis, demyelination, uveitis, toxic epidermal necrolysis, rhabdomyolysis, hemolytic anemia, sarcoidosis and retinal detachment)
- Severe infusion-related reactions
- Monitoring and laboratory tests prior to and as indicated based on clinical evaluations
- Reproductive health: female and male potential
- Pregnant and nursing women
- Pediatric and geriatric populations
- Renal impairment
For more information:
Please consult the Imjudo Product Monograph for important information relating to adverse reactions, drug interactions and dosing, which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-668-6000.
* Comparative clinical significance unknown.
† Clinical significance unknown.
References:
- IMFINZI (AstraZeneca Canada Inc.) Product Monograph. July 17, 2025.
- IMJUDO (AstraZeneca Canada Inc.) Product Monograph. June 20, 2025.
- Data on File, AstraZeneca Canada Inc. (first anti-CTLA-4 + anti-PD-1/PD-L1). November 18, 2025.
- Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1(8) (including Supplementary Appendix and Protocol). doi:10.1056/ EVIDoa2100070.